PLAINSBORO, N.J., April 2, 2020 /PRNewswire/ -- We recognize
that people with chronic diseases, including diabetes,
obesity and hemophilia, are at increased risk during this
pandemic and Novo Nordisk is taking measures to support the
communities we serve throughout the COVID-19 pandemic.
"Patients who rely on our medicines every day, our employees who
serve them, and the heroes trying to address the outbreak in our
backyard demand our singular focus. Now, during these really
challenging times, is when we all have to work together to keep our
communities, loved ones and those we care about safe and healthy,"
said Doug Langa, Executive Vice
President, North America Operations and President of Novo Nordisk
Inc. "We take these responsibilities to heart and want people to
know what we are doing and how we can help."
Availability of medicines
We have ample supplies of
medicines, including insulin, and we expect to be able to fulfill
orders and replenish pharmacies in the US throughout this pandemic.
However, because of periodic increases in demand, there may be
times when local pharmacies are temporarily out of stock of
diabetes medicines. We are working with our distributors to ensure
that there is enough inventory to fill prescriptions quickly.
Updates on product supply and other COVID-19 resources are
available at NovoNordisk-US.com/covid19.
We encourage patients to plan ahead and know that it may take
some extra time to get a prescription filled.
There are currently no delays in obtaining growth hormone or
medicines for rare bleeding disorders.
Affordability support at NovoCare.com
This pandemic
brings economic uncertainty, as well, and we have a variety of
offerings on NovoCare.com to help ease the burden so many are
facing. Available 24 hours a day, NovoCare.com has information,
including eligibility details, on our lower-cost cash program, our
free medicines assistance, and an option for those in immediate
need of insulin. Help is also available at 1.844.NOVO4ME
(1.844.668.6463).
If those with a rare bleeding disorder are looking for support,
please visit myNovoSecure.com for options.
Supporting local relief efforts
On April 1, 2020, Novo Nordisk in the US made a
commitment to donate $500,000 to
national relief organizations as well as to New York City/New Jersey/Philadelphia relief efforts, including Direct
Relief, AmeriCares, the NYC
Emergency COVID-19 Relief Fund, the New Jersey Pandemic Relief Fund
and the Philadelphia COVID-19 Relief Fund. We are also supporting
emergency assistance requests from our patient/advocacy
organizations and our local communities to address basic needs of
individuals and families. We're also expanding our matching gifts
program until June 1, 2020.
We also know that small businesses are significantly affected by
this outbreak. To support that, we have temporarily suspended our
standard contractual payment terms and we will be paying submitted
invoices immediately for nearly 500 small and diverse
companies working with Novo Nordisk across the United States.
Keeping our employees safe
Serving patients means that
our family of more than 5,000 employees has to be available and
healthy to ensure our continued operations. Starting on
March 13, following the guidance from
the CDC and local health authorities, our teams began working
remotely, allowing them to help those who count on us and their own
families.
At our manufacturing facilities, we have implemented procedures
to support the health and safety of our employees so they can
continue production of our medicines 24/7.
Novo Nordisk is supporting other efforts globally to control the
spread of coronavirus (COVID-19). More information can be found at
novonordisk.com.
About Novo Nordisk in the US
Novo Nordisk is a global
healthcare company that's been making innovative medicines to help
people with diabetes lead longer, healthier lives for 95 years.
This heritage has given us experience and capabilities that also
enable us to help people defeat other serious diseases including
obesity, rare bleeding disorders and growth disorders. We remain
steadfast in our conviction that the formula for lasting success is
to stay focused, think long-term and do business in a financially,
socially and environmentally responsible way. With U.S.
headquarters in New Jersey and production and research
facilities in six states, Novo Nordisk employs more than 5,000
people throughout the country. For more information,
visit novonordisk.us, Facebook, Instagram and Twitter.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/coronavirus-covid-19-resources-available-from-novo-nordisk-in-the-us-301034317.html
SOURCE Novo Nordisk Inc.